Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects

Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. Although the detailed molecular mechanism of acamprosate remains unclear, it has been largely known that acamprosate inhibits glutamate action in the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Psychiatry
Hlavní autoři: Nam, H W, Karpyak, V M, Hinton, D J, Geske, J R, Ho, A M C, Prieto, M L, Biernacka, J M, Frye, M A, Weinshilboum, R M, Choi, D-S
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4564571/
https://ncbi.nlm.nih.gov/pubmed/26285131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tp.2015.120
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky